Related Experiment Videos
Availability of clotting factor concentrates in genetically engineered form
1Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Transfusion Science
|February 6, 1998
Summary
Recombinant clotting factor concentrates offer new treatments for bleeding disorders like hemophilia. Future developments include advanced therapies and gene therapy for improved hemostasis.
Area of Science:
- Hematology
- Biotechnology
- Pharmacology
Background:
- Hemostatic disorders, including hemophilia A, B, and von Willebrand disease, significantly impact patient health.
- Recombinant clotting factor concentrates represent a major advancement in managing these conditions.
Purpose of the Study:
- To review the clinical outcomes of existing recombinant clotting factor products.
- To discuss the development of factor IX and von Willebrand factor concentrates.
- To explore future directions in hemophilia treatment, including second-generation products and gene therapy.
Main Methods:
- Review of clinical results of available recombinant clotting factor concentrates.
- Discussion of ongoing development of factor IX and von Willebrand factor concentrates.
- Analysis of the potential of second-generation products and gene therapy.
Main Results:
- Current recombinant clotting factor concentrates have demonstrated clinical efficacy in treating hemophilia and von Willebrand disease.
- Development is progressing for novel concentrates and advanced therapeutic strategies.
- Elucidation of protein structure/function relationships is key to future innovations.
Conclusions:
- Recombinant factor concentrates have transformed hemostatic disorder treatment.
- Future research into protein structure/function will likely yield novel therapies for both bleeding and thrombotic diseases.